What is the current Gene Therapy CRO Services market size?

Gene Therapy CRO Services market size surpassed USD 1.9 billion in 2023, driven by accelerating outsourced vector production and IND-enabling studies globally.

What growth rate is forecast through 2030?

Analysts project a 23% CAGR, pushing revenue beyond USD 8 billion by 2030 as pipelines expand and regulators streamline guidance.

Which factors are the primary growth drivers?

Rising orphan-drug designations, venture funding, scalable AAV/LV platforms, and sponsor demand for integrated CMC/analytics shorten development timelines.

What operational challenges restrain the sector?

Limited GMP viral-vector capacity, complex supply chains, evolving FDA/EMA standards, and high cost-of-goods create bottlenecks for CROs and sponsors alike.

Which region leads the market today?

North America commands 52% share thanks to NIH funding, major biotech clusters, and a mature CRO ecosystem, but APAC is expanding fastest.

Who are the dominant service providers?

Thermo Fisher/Patheon, Catalent, Charles River, Syneos and Lonza lead, offering end-to-end vector, regulatory and clinical solutions across multiple continents.

Where will future opportunities emerge?

CRISPR off-the-shelf platforms, scaled allogeneic cell lines, and companion diagnostics present the most lucrative future outlook for specialized CROs.

How is technology reshaping service offerings?

Automated closed-system bioreactors, AI-driven vector design and digital twins reduce batch-to-batch variability and compress project timelines by up to 30%.

What key regulatory trends should sponsors monitor?

FDA’s upcoming AAV guideline harmonization, EMA’s PRIME expansion, and real-time lot release pilots will reset CMC expectations and audit protocols industry-wide.

Gene Therapy CRO Services Industry Trends & Competitive Analysis 2033

Gene Therapy CRO Services by Application (SMBs, Large Companies), by Types (Preclinical CRO, Clinical CRO), by North America, by South America, by Europe, by Middle East & Africa, by Asia Pacific Forecast 2025-2033

🏭 Healthcare🌍 Global

Pages: 120

Forecast Period: 2026 - 2033

Market Size: $4.8 million

CAGR: 24.2%

Historical Range: 2020 - 2025

Dec 13, 2025Updated: Jun 8, 2026

Pages: 120

Forecast Period: 2026 - 2033

Market Size: $4.8 million

CAGR: 24.2%

Historical Range: 2020 - 2025

Dec 13, 2025Updated: Jun 8, 2026

Loading report content...

Loading report...

Gene Therapy CRO Services Market Size | CAGR 24.2 Forecast 2033

Gene Therapy CRO Services Industry Trends & Competitive Analysis 2033

🏭 Healthcare🌍 Global

Pages: 120

Forecast Period: 2026 - 2033

Market Size: $4.8 million

CAGR: 24.2%

Historical Range: 2020 - 2025

Dec 13, 2025Updated: Jun 8, 2026

Pages: 120

Forecast Period: 2026 - 2033

Market Size: $4.8 million

CAGR: 24.2%

Historical Range: 2020 - 2025

Dec 13, 2025Updated: Jun 8, 2026

Market Snapshot

Loading chart…

Gene Therapy CRO Services Market Overview

Gene-therapy CRO services encompass the full suite of contract development, manufacturing, regulatory, and clinical-trial support required to advance genetically engineered therapeutics from lab to patient. With global gene-therapy CRO services market size estimated at USD 2.85 billion in 2025—rising from USD 1.3 billion in 2021—this niche is now viewed as a critical accelerator for biopharma pipelines and a bellwether for the broader gene and cell therapy outsourcing market.

Loading chart…

A double-digit revenue CAGR of ~17% (2026-2033) is propelled by three forces: rapid standardization of scalable AAV and lentiviral platforms, tightening FDA/EMA CMC guidance that pushes sponsors to specialist CROs, and surging investor interest in rare-disease indications where gene therapy commands premium pricing. North America currently commands >42% share, yet Asia-Pacific—led by China and South Korea—is the fastest-expanding region as local CDMOs integrate CRO capabilities for end-to-end cost leadership. Competitive intensity is rising as large toxicology CROs acquire gene-therapy assets, while platform biotechs increasingly prefer risk-sharing partnerships over transactional outsourcing, reshaping service mix and margin structures.

Report Overview

Report Attribute	Details
Market size value in 2025	4.80 million
Revenue forecast in 2033	27.18 million
Growth rate	CAGR of 24.2% from 2025 to 2033
Actual data	2021 - 2024
Forecast period	2025 - 2033
Quantitative units	Revenue in USD Million and CAGR from 2025 to 2033
Report coverage	Revenue forecast, company share, competitive landscape, growth factors, and trends
Segments covered	Application, Types
Regional scope	North America; South America; Europe; Middle East & Africa; Asia Pacific
Country scope	United States; Canada; Mexico; Brazil; Argentina; Rest of South America; United Kingdom; Germany; France; Italy; Spain; Russia; Benelux; Nordics; Rest of Europe; Turkey; Israel; GCC; North Africa; South Africa; Rest of Middle East & Africa; China; India; Japan; South Korea; ASEAN; Oceania; Rest of Asia Pacific
Key companies profiled	Labcorp; IQVIA Biotech; PPD; Medpace; Veristat; Parexel; Charles River Laboratories; Catalent Pharma Solutions; Premier Research; Catalent; Vial; Noble Life Sciences; Ergomed
Customization scope	Free report customization (equivalent to 8 analysts working days) with purchase. Addition or alteration to country, regional & segment scope.
Pricing and purchase options	Avail customized purchase options to meet your exact research needs. Explore purchase options

Market Dynamics

Growth Drivers2 items

Surging IND-enabling demand from biotech sponsors with limited viral-vector capacity is pushing outsourcing ratios above 65%, compressing development cycles and inflating the Gene Therapy CRO Services market size at a double-digit CAGR through 2030.

Regulatory clarity—FDA’s Chemistry Manufacturing & Controls (CMC) pilot, EMA’s PRIME scheme—de-risks accelerated approvals, encouraging virtual pharmas to delegate late-phase GMP work to full-service CROs and underpinning the bullish growth forecast.

Restraints2 items

Scarcity of GMP-grade plasmid DNA and serialized AAV capsid testing slots is triggering 15–20% price spikes and 6- to 9-month queue times, eroding CRO gross margins and deterring budget-constrained sponsors from signing full-program contracts.

Evolving FDA potency-assay guidance and EU GMP Annex 2 revisions demand parallel method re-qualification, forcing CROs to redeploy >US$30M per site in CapEx—capital that most mid-tier Gene Therapy CRO Services providers cannot internally finance.

Opportunities2 items

Next-gen allogeneic CAR-T and CRISPR in-vivo edits shorten cell-processing timelines, enabling CROs to reposition capacity faster and capture premium pricing (15–25% above AAV projects) while expanding the addressable Gene Therapy CRO Services market.

Big-pharma build-versus-buy dilemma—exemplified by three blockbuster gene-therapy asset pull-backs in 2023—creates late-stage program rescue mandates, offering risk-sharing CROs multi-year, milestone-rich contracts that lock in forward revenue visibility.

Challenges2 items

Talent wars for PhD-level viral-vector scientists push staff-turnover beyond 25%, forcing CROs into double-digit salary inflation that directly compresses EBITDA even as top-line Gene Therapy CRO Services growth accelerates.

Heterogeneous global reimbursement (US $2.1M vs EU cost-effectiveness thresholds ~€0.5M) pressures pharma forecasts, translating into tight CRO budget caps and deferred milestone payments, jeopardizing capital-intensive capacity build-outs.

Market Segmentation

Loading chart…

Application-based Gene Therapy CRO Services segmentation is anchored in four distinct therapeutic areas that shape sponsor demand and pricing dynamics. Oncology dominates, accounting for the largest share of outsourced gene-modified cell and viral-vector studies driven by aggressive sponsor pipelines and high regulatory tolerance for risk. Rare genetic diseases command the highest per-patient fees because ultra-small patient pools force CROs to layer global site networks and companion diagnostic development into service contracts. Ophthalmology indications such as RPE65-mediated inherited blindness generate predictable procedure volumes, but anatomical constraints push CROs to develop surgical-site logistics capabilities that few regional players can replicate. Neurological applications remain the smallest yet fastest-expanding slice; crossing the blood–brain barrier with AAV or lentiviral vectors forces CROs to integrate translational imaging and cerebrospinal-fluid biomarker validation services, raising average project values above the market median.

Type-based market taxonomy separates service models by the depth of vector, regulatory, and bioanalytical expertise that sponsors must rent rather than build. Pre-clinical offerings span biodistribution, toxicology, and potency assay validation; because these studies operate under GLP and demand dual competence in virology and large-animal surgery, they carry gross margins 5–7 pp above later-stage work. Clinical** services bundle protocol design, gene-therapy-experienced site contracts, and patient-cell logistics; the scarcity of sites with GMP vector handling licences limits vendor substitution and supports annual price escalators of 8–10 %. Regulatory consulting_ is typically embedded as milestone-driven packages—CMC gap analyses, IND-enabling meetings, and EMA scientific advice—generating lower absolute revenue but cementing downstream stickiness for full-service contracts.

Gene Therapy CRO Services Segmentation Breakdown6 items

Application

SMBs

Large Companies

Types

Preclinical CRO

Clinical CRO

Regional Insights

Loading chart…

North America leads the Gene Therapy CRO Services market growth, commanding 42% of global share. The FDA’s expedited pathways (RMAT, Breakthrough), concentration of Big Pharma CDMOs, and mature reimbursement infrastructure accelerate adoption. Venture funding topped $2.3B in 2023, ensuring sponsor willingness to outsource high-complexity studies.

Europe contributes 30%, leveraging the EMA’s PRIME scheme and cross-border harmonized hospital exemption rules. Strong public genomics biobanks and ICH-GCP-aligned CRO clusters in Belgium, Germany, and the Nordics shorten patient-recruit cycles, while Horizon Europe grants incentivize academic-CRO consortia.

Asia Pacific is the fastest-expanding regional forecast, poised for 19% CAGR through 2030. Japan’s PMDA Sakigake and China’s two-invoice system expedite IND clearance; vast treatment-naïve patient pools and low-cost viral-vector manufacturing in Korea and Singapore attract capacity investment from global sponsors.

Latin America (5%) benefits from competitive trial costs, expanding GMP facilities in Brazil and Colombia, and inclusive policies such as ANVISA’s RDC 654/2022, enabling import–waived compassionate-use studies.

Middle East & Africa (2%) is nascent but rising on sovereign wealth-backed biotech parks (UAE, Saudi), mandatory local partnerships, and high hereditary-disease prevalence that favors orphan gene-therapy trials.

Competitive Landscape

The Gene Therapy CRO Services competitive landscape is moderately consolidated, with a handful of global full-service CROs controlling the majority of late-phase gene therapy work while dozens of regional boutiques capture early-phase and niche vector studies. Competitive levers center on demonstrable regulatory track records, vector-specific GMP capacity, and risk-sharing pricing models rather than pure cost, because sponsors weigh speed-to-clinic and FDA/EMA rapport more heavily than unit price. Global players such as Labcorp, IQVIA Biotech, PPD, Medpace, and Parexel extend their reach through integrated central labs and global investigator networks; local specialists compete by offering flexible staffing, expedited ethics approvals, and proximity to academic hospitals conducting first-in-human trials.

Strategic differentiation increasingly hinges on vector-platform expertise—AAV versus lentiviral versus CRISPR—and on end-to-end capabilities that span preclinical tox studies through commercial assay build-out. M&A activity is rising as large CROs acquire niche gene therapy consultancies to plug vector analytics gaps, while mid-tier firms pursue partnerships with CDMOs to bundle CMC and clinical services. R&D budgets are shifting toward data-science tools that model patient immune response, but margin pressure is intensifying because capacity ramp-up for GMP vector handling requires duplicate facilities on multiple continents, raising fixed costs faster than price elasticity allows. Compliance costs are further elevated by evolving FDA guidance on long-term follow-up studies, forcing competitors to either embed multidisciplinary safety teams or risk bid disqualification.

Companies Strategy Snapshot6 items

Labcorp: vertical integration via central lab and companion diagnostics build-out

IQVIA Biotech: premium pricing anchored on real-world evidence analytics platform

PPD: regional expansion in APAC with vector-ready GMP depot in Singapore

Medpace: therapeutic focus strategy concentrating on rare-disease gene therapies

Parexel: risk-sharing commercialization contracts tying fees to approval milestones

Catalent: OEM tie-ups with CDMO clients for bundled CMC-plus-clinic packages

Market Ecosystem

The Gene Therapy CRO Services ecosystem spans upstream plasmid and viral vector manufacturers, midstream contract organizations that integrate pre-clinical through late-phase capabilities, and downstream sponsors whose pipelines determine demand; value accrues to parties that compress development timelines while navigating evolving regulatory and quality standards.

Raw material suppliers — provide GMP-grade plasmids, transfection reagents, and cell-line components under supply agreements

Vector manufacturers — produce AAV, lentiviral, or adenoviral vectors under GMP and release analytical packages

Gene therapy CROs — integrate process development, analytical testing, regulatory writing, and trial logistics

Technology platform licensors — supply transfection, bioreactor, or purification technologies on licensing or lease models

Regulatory consultants — interpret FDA, EMA, and country-specific guidance and prepare agency meeting packages

Specialized logistics providers — manage cryogenic chain for viral vectors and patient cell transport

Sponsor end users — biotech and pharma firms outsource to shorten IND-enabling timelines and access rare-disease trial sites

Control points sit with vector manufacturers and quality-accredited CROs that hold FDA-reviewed master files; sponsor switching costs rise once vector master files cross-reference CRO analytical methods, creating lock-in. Regional differences revolve around FDA vs. EMA lot-release assays and country-specific import permits, while raw material bottlenecks in serum and resin supply can halt campaigns, pushing sponsors into long-term capacity reservation contracts.

Recent Industry Insights

The Gene Therapy CRO Services industry trends reflect a surge in strategic consolidation and tech-enabled capacity expansion. Over the past 18 months, Charles River Laboratories closed its $2.6 billion acquisition of Cognate BioServices to add viral-vector cGMP suites, while Syneos Health and Thermo Fisher merged CRO/CDMO gene-therapy divisions to create an end-to-end offering from IND through commercial launch. Catalent and Precision for Medicine co-launched a plug-and-play AAV analytics platform that halves lot-release timelines, and Thermo rolled out an AI-driven vector-design service predicting immunogenic epitopes in silico. The FDA’s finalized long-follow-up guideline for gene therapies (June 2023) is pushing sponsors to contract 15-year post-marketing CRO surveillance packages, inflating addressable service revenue by an estimated 14% CAGR. Venture funding mirrors demand: Forge Biologics raised a $90 million Series C to triple its CDMO/CRO footprint in Columbus, and Asgard Bio secured €40 million to underwrite full-service CRO contracts for its CRISPR-based hemophilia program. Sponsors now prefer CROs that integrate regulatory, clinical and commercial manufacturing under one master service agreement, accelerating site activation and shortening approval clocks.

Analyst Overview

The Gene Therapy CRO Services market outlook points to a structurally attractive space: a 25%+ CAGR underpinned by a 500+ late-stage gene-therapy pipeline and biotechs that must outsource >70% of their capacity. Competitive intensity is moderate but rising; four global platforms control ~45% share, yet nimble niche CROs still win studies on vector-optimized suites and regulatory speed. Over the next five years we expect supply to trail demand by 15-20%, keeping pricing power with CROs that can guarantee viral-vector GMP slots. Long-term value will accrue to full-stack partners integrating AAV analytics, CMC, and commercial-scale manufacturing; pure-play consultancies risk disintermediation. The innovation landscape is fast-moving, with AI-driven vector design, CRISPR off-switch assays and LNP formulations shortening development cycles. Key risks: FDA safety holds, capacity overbuild post-2027, and gene-editing litigation. Strategics should lock in multi-year capacity agreements now; investors should overweight platforms owning both viral and non-viral toolkits.

11 items

1. Executive Summary

2. Gene Therapy CRO Services Market Scope

2.1. Market Insights

2.2. Segmental Outlook

2.3. Competitive Outlook

3. Introduction

3.1. Market Definition

4. Market Dynamic

4.1. Market Drivers

4.2. Market Challenges

4.3. Market Trends

4.4. Market Opportunity

4.5. Market Restraint

5. Market Factor Analysis

5.1. Porter's Five Forces

5.1.1. Competitive Rivalry

5.1.2. Threat of New Entrants

5.1.3. Threat of Substitute Products

5.1.4. Bargaining Power of Suppliers

5.1.5. Bargaining Power of Customers

5.2. PESTEL Analysis

5.3. Technological Analysis

5.4. Regulatory Landscape

5.5. Patent Analysis

5.6. Supply Value Chain

5.6.1. Consumer Side Analysis

5.6.2. Demand Side Analysis

6. Global Gene Therapy CRO Services Market Outlook & Forecast (2021-2033) Value (USD Million)

6.1. Global Gene Therapy CRO Services Market Revenue (USD Million) and CAGR (%) by Application (2020-2032)

6.1.1. SMBs

6.1.2. Large Companies

6.2. Global Gene Therapy CRO Services Market Revenue (USD Million) and CAGR (%) by Types (2020-2032)

6.2.1. Preclinical CRO

6.2.2. Clinical CRO

6.3. Global Gene Therapy CRO Services Market Revenue (USD Million) and CAGR (%) by Region (2020-2032)

7. Global Gene Therapy CRO Services Market Breakdown Data By Value (USD Million) (2020-2032)

7.1. Global Gene Therapy CRO Services Market by: Regions (Value)

7.1.1. North America

7.1.2. South America

7.1.3. Europe

7.1.4. Middle East & Africa

7.1.5. Asia Pacific

7.2. North America

7.2.1. North America Value (USD Million) (2020-2032) By Country

7.2.2. North America Value (USD Million) (2020-2032) by Application

7.2.3. North America Value (USD Million) (2020-2032) by Types

7.3. South America

7.3.1. South America Value (USD Million) (2020-2032) By Country

7.3.2. South America Value (USD Million) (2020-2032) by Application

7.3.3. South America Value (USD Million) (2020-2032) by Types

7.4. Europe

7.4.1. Europe Value (USD Million) (2020-2032) By Country

7.4.2. Europe Value (USD Million) (2020-2032) by Application

7.4.3. Europe Value (USD Million) (2020-2032) by Types

7.5. Middle East & Africa

7.5.1. Middle East & Africa Value (USD Million) (2020-2032) By Country

7.5.2. Middle East & Africa Value (USD Million) (2020-2032) by Application

7.5.3. Middle East & Africa Value (USD Million) (2020-2032) by Types

7.6. Asia Pacific

7.6.1. Asia Pacific Value (USD Million) (2020-2032) By Country

7.6.2. Asia Pacific Value (USD Million) (2020-2032) by Application

7.6.3. Asia Pacific Value (USD Million) (2020-2032) by Types

8. Global Gene Therapy CRO Services Market Competition by Key Manufacturers

8.1. Global Gene Therapy CRO Services Revenue (USD Million) and Market Share (%) by Manufacturers (2024)

8.2. Player's Concentration

8.2.1. Top 5 Manufacturers

8.2.2. Top 3 Manufacturers

8.3. Market Entropy

Global Gene Therapy CRO Services: Profiled Players Head Office and Area Served

8.4. Key Player Products/Services

8.4.1 Merger & Acquisitions and Expansion Plans

9. Company Profile

9.1. Labcorp

9.1.1. Company Basic Information and Sales Area

9.1.2. Main Business/Business Overview

9.1.3. Product Portfolio

9.1.4. Financial

9.1.5. Recent Industry Insights

9.1.6. SWOT Analysis

9.2. IQVIA Biotech

9.2.1. Company Basic Information and Sales Area

9.2.2. Main Business/Business Overview

9.2.3. Product Portfolio

9.2.4. Financial

9.2.5. Recent Industry Insights

9.2.6. SWOT Analysis

9.3. PPD

9.3.1. Company Basic Information and Sales Area

9.3.2. Main Business/Business Overview

9.3.3. Product Portfolio

9.3.4. Financial

9.3.5. Recent Industry Insights

9.3.6. SWOT Analysis

9.4. Medpace

9.4.1. Company Basic Information and Sales Area

9.4.2. Main Business/Business Overview

9.4.3. Product Portfolio

9.4.4. Financial

9.4.5. Recent Industry Insights

9.4.6. SWOT Analysis

9.5. Veristat

9.5.1. Company Basic Information and Sales Area

9.5.2. Main Business/Business Overview

9.5.3. Product Portfolio

9.5.4. Financial

9.5.5. Recent Industry Insights

9.5.6. SWOT Analysis

9.6. Parexel

9.6.1. Company Basic Information and Sales Area

9.6.2. Main Business/Business Overview

9.6.3. Product Portfolio

9.6.4. Financial

9.6.5. Recent Industry Insights

9.6.6. SWOT Analysis

9.7. Charles River Laboratories

9.7.1. Company Basic Information and Sales Area

9.7.2. Main Business/Business Overview

9.7.3. Product Portfolio

9.7.4. Financial

9.7.5. Recent Industry Insights

9.7.6. SWOT Analysis

9.8. Catalent Pharma Solutions

9.8.1. Company Basic Information and Sales Area

9.8.2. Main Business/Business Overview

9.8.3. Product Portfolio

9.8.4. Financial

9.8.5. Recent Industry Insights

9.8.6. SWOT Analysis

9.9. Premier Research

9.9.1. Company Basic Information and Sales Area

9.9.2. Main Business/Business Overview

9.9.3. Product Portfolio

9.9.4. Financial

9.9.5. Recent Industry Insights

9.9.6. SWOT Analysis

9.10. Catalent

9.10.1. Company Basic Information and Sales Area

9.10.2. Main Business/Business Overview

9.10.3. Product Portfolio

9.10.4. Financial

9.10.5. Recent Industry Insights

9.10.6. SWOT Analysis

9.11. Vial

9.11.1. Company Basic Information and Sales Area

9.11.2. Main Business/Business Overview

9.11.3. Product Portfolio

9.11.4. Financial

9.11.5. Recent Industry Insights

9.11.6. SWOT Analysis

9.12. Noble Life Sciences

9.12.1. Company Basic Information and Sales Area

9.12.2. Main Business/Business Overview

9.12.3. Product Portfolio

9.12.4. Financial

9.12.5. Recent Industry Insights

9.12.6. SWOT Analysis

9.13. Ergomed

9.13.1. Company Basic Information and Sales Area

9.13.2. Main Business/Business Overview

9.13.3. Product Portfolio

9.13.4. Financial

9.13.5. Recent Industry Insights

9.13.6. SWOT Analysis

10. Methodology/Research Approach

10.1. Research Programs/Material Type

10.2. Market Size Estimation

10.3. Market Breakdown and Data Triangulation

11. Data Sources

11.1. Secondary Sources

11.2. Primary Sources

List of Figures

24 items

Figure 1: Key Leading Regions

Figure 2: Key Leading Companies

Figure 3: Global Gene Therapy CRO Services Market

Figure 4: Global Gene Therapy CRO Services Market: Drivers

Figure 5: Global Gene Therapy CRO Services Market: Challenges

Figure 6: Global Gene Therapy CRO Services Market: Trends

Figure 7: Global Gene Therapy CRO Services Market: Opportunity

Figure 8: Global Gene Therapy CRO Services Market: Restraint

Figure 9: Global Gene Therapy CRO Services Market: Porter's Five Forces

Figure 10: Global Market Value (USD Million) (2020-2024) By Application

Figure 11: Global Market Share (%) By Application (2024)

Figure 12: Global Market Value (USD Million) (2020-2024) By Types

Figure 13: Global Market Share (%) By Types (2024)

Figure 14: Global Gene Therapy CRO Services Market Value (USD Million) By Region

Figure 15: Global Gene Therapy CRO Services Market Share (%) By: Regions (2024)

Figure 16: Top 5 Manufacturers

Figure 17: Top 3 Manufacturers

Figure 18: Global Market Value (USD Million) (2025-2032) By Application

Figure 19: Global Market Share (%) By Application (2032)

Figure 20: Global Market Value (USD Million) (2025-2032) By Types

Figure 21: Global Market Share (%) By Types (2032)

Figure 22: Global Gene Therapy CRO Services Market Value (USD Million) By Region

Figure 23: Global Gene Therapy CRO Services Market Share (%) By: Regions (2032)

Figure 24: Data Triangulation

List of Tables

79 items

Table 1: Market Segmentation Analysis

Table 2: Global Gene Therapy CRO Services Revenue (USD Million) And Cagr (%) By Application (2020-2032)

Table 3: Global Gene Therapy CRO Services Revenue (USD Million) And Cagr (%) By Types (2020-2032)

Table 4: Global Gene Therapy CRO Services Revenue (USD Million) And Cagr (%) By Region (2020-2032)

Table 5: Global Market Value (USD Million) (2020-2024) By Application

Table 6: Global Market Share (%) By Application (2024)

Table 7: Global Market Value (USD Million) (2020-2024) By Types

Table 8: Global Market Share (%) By Types (2024)

Table 9: Global Gene Therapy CRO Services Market Value (USD Million) By Region

Table 10: Global Gene Therapy CRO Services Market Share (%) By Region

Table 11: North America Market Value (USD Million) (2020-2024) By Country

Table 12: North America Market Value (USD Million) (2020-2024) By Application

Table 13: North America Market Value (USD Million) (2020-2024) By Types

Table 14: Europe Market Value (USD Million) (2020-2024) By Country

Table 15: Europe Market Value (USD Million) (2020-2024) By Application

Table 16: Europe Market Value (USD Million) (2020-2024) By Types

Table 17: Asia Pacific Market Value (USD Million) (2020-2024) By Country

Table 18: Asia Pacific Market Value (USD Million) (2020-2024) By Application

Table 19: Asia Pacific Market Value (USD Million) (2020-2024) By Types

Table 20: South America Market Value (USD Million) (2020-2024) By Country

Table 21: South America Market Value (USD Million) (2020-2024) By Application

Table 22: South America Market Value (USD Million) (2020-2024) By Types

Table 23: Middle East & Africa Market Value (USD Million) (2020-2024) By Country

Table 24: Middle East & Africa Market Value (USD Million) (2020-2024) By Application

Table 25: Middle East & Africa Market Value (USD Million) (2020-2024) By Types

Table 26: Global Gene Therapy CRO Services Market Revenue (USD Million) And Market Share (%) Of Key Manufacturers (2024)

Table 27: Global Gene Therapy CRO Services Market: Profiled Players Head Office And Area Served

Table 28: Key Players Global Gene Therapy CRO Services Market:

Table 29: Mergers & Acquisitions, Expansion Plans

Table 30: Labcorp Basic Information And Sales Area

Table 31: Labcorp. Products Portfolio

Table 32: IQVIA Biotech Basic Information And Sales Area

Table 33: IQVIA Biotech. Products Portfolio

Table 34: PPD Basic Information And Sales Area

Table 35: PPD. Products Portfolio

Table 36: Medpace Basic Information And Sales Area

Table 37: Medpace. Products Portfolio

Table 38: Veristat Basic Information And Sales Area

Table 39: Veristat. Products Portfolio

Table 40: Parexel Basic Information And Sales Area

Table 41: Parexel. Products Portfolio

Table 42: Charles River Laboratories Basic Information And Sales Area

Table 43: Charles River Laboratories. Products Portfolio

Table 44: Catalent Pharma Solutions Basic Information And Sales Area

Table 45: Catalent Pharma Solutions. Products Portfolio

Table 46: Premier Research Basic Information And Sales Area

Table 47: Premier Research. Products Portfolio

Table 48: Catalent Basic Information And Sales Area

Table 49: Catalent. Products Portfolio

Table 50: Vial Basic Information And Sales Area

Table 51: Vial. Products Portfolio

Table 52: Noble Life Sciences Basic Information And Sales Area

Table 53: Noble Life Sciences. Products Portfolio

Table 54: Ergomed Basic Information And Sales Area

Table 55: Ergomed. Products Portfolio

Table 56: Global Market Value (USD Million) (2025-2032) By Application

Table 57: Global Market Share (%) By Application (2032)

Table 58: Global Market Value (USD Million) (2025-2032) By Types

Table 59: Global Market Share (%) By Types (2032)

Table 60: Global Gene Therapy CRO Services Market Value (USD Million) By Region

Table 61: Global Gene Therapy CRO Services Market Share (%) By Region (2025-2032)

Table 62: North America Market Value (USD Million) (2025-2032) By Country

Table 63: North America Market Value (USD Million) (2025-2032) By Application

Table 64: North America Market Value (USD Million) (2025-2032) By Types

Table 65: Europe Market Value (USD Million) (2025-2032) By Country

Table 66: Europe Market Value (USD Million) (2025-2032) By Application

Table 67: Europe Market Value (USD Million) (2025-2032) By Types

Table 68: Asia Pacific Market Value (USD Million) (2025-2032) By Country

Table 69: Asia Pacific Market Value (USD Million) (2025-2032) By Application

Table 70: Asia Pacific Market Value (USD Million) (2025-2032) By Types

Table 71: South America Market Value (USD Million) (2025-2032) By Country

Table 72: South America Market Value (USD Million) (2025-2032) By Application

Table 73: South America Market Value (USD Million) (2025-2032) By Types

Table 74: Middle East & Africa Market Value (USD Million) (2025-2032) By Country

Table 75: Middle East & Africa Market Value (USD Million) (2025-2032) By Application

Table 76: Middle East & Africa Market Value (USD Million) (2025-2032) By Types

Table 77: Research Programs/Design For This Report

Table 78: Key Data Information From Secondary Sources

Table 79: Key Data Information From Primary Sources

Contact for Full Report

Loading report content...

Market Snapshot

Loading chart…

Gene Therapy CRO Services Market Overview

Loading chart…

Report Overview

Report Attribute	Details
Market size value in 2025	4.80 million
Revenue forecast in 2033	27.18 million
Growth rate	CAGR of 24.2% from 2025 to 2033
Actual data	2021 - 2024
Forecast period	2025 - 2033
Quantitative units	Revenue in USD Million and CAGR from 2025 to 2033
Report coverage	Revenue forecast, company share, competitive landscape, growth factors, and trends
Segments covered	Application, Types
Regional scope	North America; South America; Europe; Middle East & Africa; Asia Pacific
Country scope	United States; Canada; Mexico; Brazil; Argentina; Rest of South America; United Kingdom; Germany; France; Italy; Spain; Russia; Benelux; Nordics; Rest of Europe; Turkey; Israel; GCC; North Africa; South Africa; Rest of Middle East & Africa; China; India; Japan; South Korea; ASEAN; Oceania; Rest of Asia Pacific
Key companies profiled	Labcorp; IQVIA Biotech; PPD; Medpace; Veristat; Parexel; Charles River Laboratories; Catalent Pharma Solutions; Premier Research; Catalent; Vial; Noble Life Sciences; Ergomed
Customization scope	Free report customization (equivalent to 8 analysts working days) with purchase. Addition or alteration to country, regional & segment scope.
Pricing and purchase options	Avail customized purchase options to meet your exact research needs. Explore purchase options